Abstract
Summary
The global Neurological Drugs market size is projected to grow from US$ 115430 million in 2022 to US$ 193720 million in 2029; it is expected to grow at a CAGR of 7.7% from 2023 to 2029.
United States market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neurological Drugs players cover Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck and Allergan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
LPI (LP Information)' newest research report, the “Neurological Drugs Industry Forecast” looks at past sales and reviews total world Neurological Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neurological Drugs sales for 2023 through 2029. With Neurological Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neurological Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Non-prescription drugs
Prescription
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
North China Pharmaceutical
Harbin Pharmaceutical Co., Ltd.
Lukang Pharmaceutical
Kelun Pharmaceutical
Kehua Biology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Drugs market?
What factors are driving Neurological Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Drugs market opportunities vary by end market size?
How does Neurological Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Neurological Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Neurological Drugs players cover Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck and Allergan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
LPI (LP Information)' newest research report, the “Neurological Drugs Industry Forecast” looks at past sales and reviews total world Neurological Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Neurological Drugs sales for 2023 through 2029. With Neurological Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Neurological Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Non-prescription drugs
Prescription
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
North China Pharmaceutical
Harbin Pharmaceutical Co., Ltd.
Lukang Pharmaceutical
Kelun Pharmaceutical
Kehua Biology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Drugs market?
What factors are driving Neurological Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Drugs market opportunities vary by end market size?
How does Neurological Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurological Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Neurological Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Neurological Drugs by Country/Region, 2018, 2022 & 2029
2.2 Neurological Drugs Segment by Type
2.2.1 Non-prescription drugs
2.2.2 Prescription
2.3 Neurological Drugs Sales by Type
2.3.1 Global Neurological Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Neurological Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Neurological Drugs Sale Price by Type (2018-2023)
2.4 Neurological Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Neurological Drugs Sales by Application
2.5.1 Global Neurological Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Neurological Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Neurological Drugs Sale Price by Application (2018-2023)
3 Global Neurological Drugs by Company
3.1 Global Neurological Drugs Breakdown Data by Company
3.1.1 Global Neurological Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Neurological Drugs Sales Market Share by Company (2018-2023)
3.2 Global Neurological Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Neurological Drugs Revenue by Company (2018-2023)
3.2.2 Global Neurological Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Neurological Drugs Sale Price by Company
3.4 Key Manufacturers Neurological Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurological Drugs Product Location Distribution
3.4.2 Players Neurological Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Neurological Drugs by Geographic Region
4.1 World Historic Neurological Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Neurological Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Neurological Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Neurological Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Neurological Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Neurological Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Neurological Drugs Sales Growth
4.4 APAC Neurological Drugs Sales Growth
4.5 Europe Neurological Drugs Sales Growth
4.6 Middle East & Africa Neurological Drugs Sales Growth
5 Americas
5.1 Americas Neurological Drugs Sales by Country
5.1.1 Americas Neurological Drugs Sales by Country (2018-2023)
5.1.2 Americas Neurological Drugs Revenue by Country (2018-2023)
5.2 Americas Neurological Drugs Sales by Type
5.3 Americas Neurological Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Drugs Sales by Region
6.1.1 APAC Neurological Drugs Sales by Region (2018-2023)
6.1.2 APAC Neurological Drugs Revenue by Region (2018-2023)
6.2 APAC Neurological Drugs Sales by Type
6.3 APAC Neurological Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neurological Drugs by Country
7.1.1 Europe Neurological Drugs Sales by Country (2018-2023)
7.1.2 Europe Neurological Drugs Revenue by Country (2018-2023)
7.2 Europe Neurological Drugs Sales by Type
7.3 Europe Neurological Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurological Drugs by Country
8.1.1 Middle East & Africa Neurological Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Neurological Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Neurological Drugs Sales by Type
8.3 Middle East & Africa Neurological Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurological Drugs
10.3 Manufacturing Process Analysis of Neurological Drugs
10.4 Industry Chain Structure of Neurological Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurological Drugs Distributors
11.3 Neurological Drugs Customer
12 World Forecast Review for Neurological Drugs by Geographic Region
12.1 Global Neurological Drugs Market Size Forecast by Region
12.1.1 Global Neurological Drugs Forecast by Region (2024-2029)
12.1.2 Global Neurological Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neurological Drugs Forecast by Type
12.7 Global Neurological Drugs Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Neurological Drugs Product Portfolios and Specifications
13.1.3 Pfizer Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Ely Lilly
13.2.1 Ely Lilly Company Information
13.2.2 Ely Lilly Neurological Drugs Product Portfolios and Specifications
13.2.3 Ely Lilly Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Ely Lilly Main Business Overview
13.2.5 Ely Lilly Latest Developments
13.3 Actavis
13.3.1 Actavis Company Information
13.3.2 Actavis Neurological Drugs Product Portfolios and Specifications
13.3.3 Actavis Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Actavis Main Business Overview
13.3.5 Actavis Latest Developments
13.4 Mylan
13.4.1 Mylan Company Information
13.4.2 Mylan Neurological Drugs Product Portfolios and Specifications
13.4.3 Mylan Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Mylan Main Business Overview
13.4.5 Mylan Latest Developments
13.5 Randox
13.5.1 Randox Company Information
13.5.2 Randox Neurological Drugs Product Portfolios and Specifications
13.5.3 Randox Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Randox Main Business Overview
13.5.5 Randox Latest Developments
13.6 Intellipharmaceutics
13.6.1 Intellipharmaceutics Company Information
13.6.2 Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
13.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Intellipharmaceutics Main Business Overview
13.6.5 Intellipharmaceutics Latest Developments
13.7 Astrazeneca
13.7.1 Astrazeneca Company Information
13.7.2 Astrazeneca Neurological Drugs Product Portfolios and Specifications
13.7.3 Astrazeneca Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Astrazeneca Main Business Overview
13.7.5 Astrazeneca Latest Developments
13.8 Lundbeck
13.8.1 Lundbeck Company Information
13.8.2 Lundbeck Neurological Drugs Product Portfolios and Specifications
13.8.3 Lundbeck Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Lundbeck Main Business Overview
13.8.5 Lundbeck Latest Developments
13.9 Allergan
13.9.1 Allergan Company Information
13.9.2 Allergan Neurological Drugs Product Portfolios and Specifications
13.9.3 Allergan Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Allergan Main Business Overview
13.9.5 Allergan Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Neurological Drugs Product Portfolios and Specifications
13.10.3 GSK Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Otsuka Pharmaceutical
13.11.1 Otsuka Pharmaceutical Company Information
13.11.2 Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Otsuka Pharmaceutical Main Business Overview
13.11.5 Otsuka Pharmaceutical Latest Developments
13.12 Takeda
13.12.1 Takeda Company Information
13.12.2 Takeda Neurological Drugs Product Portfolios and Specifications
13.12.3 Takeda Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Takeda Main Business Overview
13.12.5 Takeda Latest Developments
13.13 NHU Group
13.13.1 NHU Group Company Information
13.13.2 NHU Group Neurological Drugs Product Portfolios and Specifications
13.13.3 NHU Group Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NHU Group Main Business Overview
13.13.5 NHU Group Latest Developments
13.14 Shionogi
13.14.1 Shionogi Company Information
13.14.2 Shionogi Neurological Drugs Product Portfolios and Specifications
13.14.3 Shionogi Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Shionogi Main Business Overview
13.14.5 Shionogi Latest Developments
13.15 APOTEX
13.15.1 APOTEX Company Information
13.15.2 APOTEX Neurological Drugs Product Portfolios and Specifications
13.15.3 APOTEX Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 APOTEX Main Business Overview
13.15.5 APOTEX Latest Developments
13.16 North China Pharmaceutical
13.16.1 North China Pharmaceutical Company Information
13.16.2 North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 North China Pharmaceutical Main Business Overview
13.16.5 North China Pharmaceutical Latest Developments
13.17 Harbin Pharmaceutical Co., Ltd.
13.17.1 Harbin Pharmaceutical Co., Ltd. Company Information
13.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
13.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Harbin Pharmaceutical Co., Ltd. Main Business Overview
13.17.5 Harbin Pharmaceutical Co., Ltd. Latest Developments
13.18 Lukang Pharmaceutical
13.18.1 Lukang Pharmaceutical Company Information
13.18.2 Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Lukang Pharmaceutical Main Business Overview
13.18.5 Lukang Pharmaceutical Latest Developments
13.19 Kelun Pharmaceutical
13.19.1 Kelun Pharmaceutical Company Information
13.19.2 Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
13.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Kelun Pharmaceutical Main Business Overview
13.19.5 Kelun Pharmaceutical Latest Developments
13.20 Kehua Biology
13.20.1 Kehua Biology Company Information
13.20.2 Kehua Biology Neurological Drugs Product Portfolios and Specifications
13.20.3 Kehua Biology Neurological Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Kehua Biology Main Business Overview
13.20.5 Kehua Biology Latest Developments
14 Research Findings and Conclusion